Lupus (SLE): vizsgálatok itt: Japán
20 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Fukuoka, Kanazawa, Maebashi, Nagoya, Sapporo, Yokohama
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 3. fázisTaking peoplePhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Where
- Bunkyo Ku, Chuo Ku, Fuchū, Miyazaki, Nagoya, Osaka, Sapporo, Sendai, Shinjuku Ku, tabashi City, Yokohama
- Életkor
- 12 év to 100 év
- People
- 550 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- Where
- Asahikawa-shi, Bunkyo-ku, Chiba, Chūō, Chūōku, Fukushima, Kanazawa, Kitakyushu-shi, Kobe, Nagoya, Okayama, Sapporo, Sendai, Suita-shi, tabashi City, Yokohama
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00 - 3. fázisTaking peopleA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Where
- Aichi, Bunkyō City, Chiba, Chūō, Fuchū, Fukuoka, Fukushima, Isehara, Naha, Osaka, Sapporo, Sendai, Shimane, Shinjuku-Ku, Tokyo, Toyama
- Életkor
- 18 év to 75 év
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Where
- Bunkyō City, Chūōku, Fukuoka, Kawagoe, Kawasaki-shi, Kita-gun, Kitakyushu, Kurashiki, Kyoto, Meguro-ku, Nagasaki, Nagoya, Osaka, Saga, Sagamihara, Sapporo, Sasebo, Sendai, Shinjuku-ku, Suita, Suita-shi, Toyoake-shi, Tsu, Wakayama, Yokohama, Yoshida-gun
- Életkor
- 16 év and over
- People
- 450 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00 - No phaseTaking peopleA Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Where
- Kitakyushu-shi, Sendai, Toyama, Wakayama
- Életkor
- 16 év and over
- People
- 223 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07175285 - 1. fázisTaking peopleA Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
- Where
- Bunkyo, Shinjyuku
- Életkor
- 18 év to 75 év
- People
- 21 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07363590 · EU 2025-523412-36-00 - 2. fázisTaking peopleA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Where
- Aichi, Nagoya, Chiba, Chiba, Chiba, Urayasu, Fukuoka, Kitakyushu, Hokkaido, Sapporo, Miyagi, Sendai, Miyazaki, Miyazaki, Nagano, Matsumoto, Niigata, Niigata, Okayama, Okayama, Saitama, Iruma-gun, Tokyo, Bunkyo-ku, Tokyo, Chuo-ku, Tokyo, Shinjuku-ku
- Életkor
- 18 év to 74 év
- People
- 405 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00 - 2. fázisTaking peopleA Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
- Where
- Ginowan-shi, Kagoshima, Kanazawa, Niigata, Setagaya-ku
- Életkor
- 5 év to 17 év
- People
- 24 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07630714 · EU 2025-524578-41-00 - No phaseTaking peopleLUPKYNIS Drug-use Results Survey
- Where
- Osaka
- Életkor
- 15 év and over
- People
- 400
- Run by
- Otsuka Pharmaceutical Co., Ltd.
See details and how to joinNCT07053891 - 1. fázisTaking peopleA Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Where
- Bunkyo-ku, Nagoya, Shinjuku-ku
- Életkor
- 18 év to 75 év
- People
- 30 worldwide
- Run by
- AbbVie
See details and how to joinNCT07607964 - 1. fázisTaking peopleA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Where
- Bunkyō City, Kita-gun, Kitakyushu-shi, Kyoto, Nagasaki
- Életkor
- 18 év to 70 év
- People
- 72 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00 - 3. fázisCsak meghívásosA Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
- Where
- Nagoya
- Életkor
- 16 év and over
- People
- 760 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00 - 1. fázisTaking peopleA Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Where
- Shinjuku-ku
- Életkor
- 18 év to 55 év
- People
- 68 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07276958 · EU 2026-527207-25-00 - 3. fázisCsak meghívásosA Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
- Where
- Chiba, Fukuoka, Himeji-shi, Hiroshima, Kagoshima, Kawachinagano-shi, Kita-gun, Kitakyushu-shi, Kobe, Kumamoto, Meguro-ku, Nagoya, Osakasayama-Shi, Sapporo, Shinjuku-Ku, tabashi City, Toyoake-shi, Yokohama
- Életkor
- 18 év and over
- People
- 864 worldwide
- Run by
- Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00 - 3. fázisTaking peopleAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Where
- Bunkyō City, Chiba, Fuchu-shi, Kawasaki-shi, Kobe, Nagasaki, Obu-shi, Shinjuku-ku, Yokohama
- Életkor
- 5 év to 17 év
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00 - 2. fázisTaking peopleA Study of E6742 in Participants With Systemic Lupus Erythematosus
- Where
- Bunkyo, Fuchū, Fukuoka, Hiroshima, Kitakyushu, Kobe, Kumamoto, Mibu-Machi, Shimotsugagun, Nagoya, Naha, Niigata, Nishinomiya, Okayama, Ōta-ku, Sapporo, Sendai, Shinjuku, Toyoake
- Életkor
- 18 év to 75 év
- People
- 256 worldwide
- Run by
- Eisai Co., Ltd.
See details and how to joinNCT07515014 - No phaseTaking peopleStudy to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
- Where
- Fukuoka
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06527872 - 1. fázisTaking peopleA Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- Where
- Fukuoka, Hiroshima, Hokkaido
- Életkor
- 18 év to 70 év
- People
- 44 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00 - No phaseTaking peopleValidation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region
- Where
- Kitakyushu, Tokyo
- Életkor
- 18 év and over
- People
- 5000 worldwide
- Run by
- Monash University
See details and how to joinNCT03138941